Author

Anushree R. Iyengar

Observed name: Anushree Iyengar

Institution: Nference (United States)

Observed institution: Nference (United States)

ORCID: 0009-0000-3561-7818

Observed ORCID: 0009-0000-3561-7818

OpenAlex ID: A5108926261

Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status.

2024 · Sandhya Mehta, Anushree Iyengar, et al. · Journal of Clinical Oncology · 14

Impact of empirical treatment failure on health care resource utilization and costs among female patients with uncomplicated urinary tract infections in a US-based Integrated Health Delivery Network

2025 · Jeffrey J. Ellis, Anushree Iyengar, et al. · Journal of Managed Care & Specialty Pharmacy · 4

THU-135 Real-world study of reasons for non-utilization of second-line treatment in patients with primary biliary cholangitis

2024 · Seema T. Meloni, Claudia O. Zein, et al. · Journal of Hepatology · 4

HER2‐Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0

2026 · Anushree R. Iyengar, Erinn P. Downs, et al. · The Breast Journal

Mo1590 RELIABILITY OF USING BINARY BIOCHEMICAL CRITERIA AT MONTH 6 FOR PREDICTING TREATMENT OUTCOMES IN PRIMARY BILIARY CHOLANGITIS

2024 · Seema T. Meloni, Claudia O. Zein, et al. · Gastroenterology

Mo1604 REAL-WORLD STUDY TO EXAMINE BASELINE CHARACTERISTICS, CONCURRENT AUTOIMMUNE CONDITIONS AND ENVIRONMENTAL EXPOSURES AS POSSIBLE PREDICTORS OF RESPONSE TO URSODEOXYCHOLIC ACID FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS

2024 · Seema T. Meloni, Claudia O. Zein, et al. · Gastroenterology

Works count: 6

Citation count: 22

H-index: 3

I10-index: 1